X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare PLETHICO PHARMA with AANJANEYA LIFECARE - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PLETHICO PHARMA vs DR. DATSONS LABS - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PLETHICO PHARMA DR. DATSONS LABS PLETHICO PHARMA/
DR. DATSONS LABS
 
P/E (TTM) x -1.1 -10.9 - View Chart
P/BV x 0.0 0.2 10.3% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 PLETHICO PHARMA   DR. DATSONS LABS
EQUITY SHARE DATA
    PLETHICO PHARMA
Mar-14
DR. DATSONS LABS
Mar-14
PLETHICO PHARMA/
DR. DATSONS LABS
5-Yr Chart
Click to enlarge
High Rs395126 314.4%   
Low Rs3131 101.3%   
Sales per share (Unadj.) Rs604.4133.0 454.5%  
Earnings per share (Unadj.) Rs32.50.2 21,422.5%  
Cash flow per share (Unadj.) Rs51.36.6 776.8%  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs473.6128.8 367.7%  
Shares outstanding (eoy) m34.0831.66 107.6%   
Bonus/Rights/Conversions -FCCB-  
Price / Sales ratio x0.40.6 59.9%   
Avg P/E ratio x6.6516.1 1.3%  
P/CF ratio (eoy) x4.211.8 35.1%  
Price / Book Value ratio x0.50.6 74.1%  
Dividend payout %00-   
Avg Mkt Cap Rs m7,2622,477 293.1%   
No. of employees `000NANA-   
Total wages/salary Rs m1,59656 2,850.0%   
Avg. sales/employee Rs ThNMNM-  
Avg. wages/employee Rs ThNMNM-  
Avg. net profit/employee Rs ThNMNM-  
INCOME DATA
Net Sales Rs m20,5984,211 489.2%  
Other income Rs m38679 490.9%   
Total revenues Rs m20,9844,289 489.2%   
Gross profit Rs m2,818569 495.5%  
Depreciation Rs m642204 314.2%   
Interest Rs m1,593430 370.3%   
Profit before tax Rs m96913 7,626.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-2 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-1386 -2,268.5%   
Profit after tax Rs m1,1075 23,060.0%  
Gross profit margin %13.713.5 101.3%  
Effective tax rate %-14.348.0 -29.7%   
Net profit margin %5.40.1 4,713.8%  
BALANCE SHEET DATA
Current assets Rs m18,8776,852 275.5%   
Current liabilities Rs m11,8966,711 177.3%   
Net working cap to sales %33.93.3 1,012.0%  
Current ratio x1.61.0 155.4%  
Inventory Days Days36161 22.3%  
Debtors Days Days198318 62.1%  
Net fixed assets Rs m9,8613,673 268.5%   
Share capital Rs m341317 107.6%   
"Free" reserves Rs m12,3313,761 327.9%   
Net worth Rs m16,1394,078 395.8%   
Long term debt Rs m4,7061,671 281.6%   
Total assets Rs m33,14612,633 262.4%  
Interest coverage x1.61.0 156.2%   
Debt to equity ratio x0.30.4 71.2%  
Sales to assets ratio x0.60.3 186.4%   
Return on assets %8.13.4 236.6%  
Return on equity %6.90.1 5,826.2%  
Return on capital %12.37.7 160.2%  
Exports to sales %21.422.9 93.4%   
Imports to sales %15.214.3 106.5%   
Exports (fob) Rs m4,402964 456.7%   
Imports (cif) Rs m3,136602 521.0%   
Fx inflow Rs m4,402964 456.7%   
Fx outflow Rs m3,184607 524.4%   
Net fx Rs m1,219357 341.4%   
CASH FLOW
From Operations Rs m2,4371,345 181.2%  
From Investments Rs m-6,265-2,256 277.7%  
From Financial Activity Rs m2,490-1,200 -207.5%  
Net Cashflow Rs m-1,337-2,111 63.4%  

Share Holding

Indian Promoters % 82.7 4.5 1,825.6%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 4.3 0.0 -  
FIIs % 5.5 1.4 407.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 7.5 94.1 8.0%  
Shareholders   10,665 20,807 51.3%  
Pledged promoter(s) holding % 85.7 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PLETHICO PHARMA With:   DR. REDDYS LAB  STERLING BIOTECH  ASTRAZENECA PHARMA  AUROBINDO PHARMA  IPCA LABS  

Compare PLETHICO PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Strong Finish to the Week; Metal & Pharma Stocks Gain(Closing)

Indian share markets finished the trading session on a strong note amid firm Asian markets after comments from a Federal Reserve official eased worries about faster rate hikes in US.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PLETHICO PHARMA SHARE PRICE


Jun 13, 2016 (Close)

TRACK PLETHICO PHARMA

  • Track your investment in PLETHICO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PLETHICO PHARMA

PLETHICO PHARMA 8-QTR ANALYSIS

COMPARE PLETHICO PHARMA WITH

MARKET STATS